Find the Right Companion Diagnostic

Oncomine Dx Target Test is an FDA-approved, qualitative targeted NGS assay performed on the Ion PGM Dx System. Using DNA and RNA from FFPE tumor tissue, it detects single-nucleotide variants, insertions, deletions, and fusions in a defined panel of cancer driver genes. It is approved for use in NSCLC and several other solid tumors to characterize oncogenic alterations and support selection of targeted treatment strategies.

MMR IHC Panel pharmDx is an FDA-approved, qualitative immunohistochemical assay performed on the Dako Omnis platform to assess MLH1, PMS2, MSH2, and MSH6 protein expression in FFPE colorectal cancer tissue. By determining mismatch repair–deficient (dMMR) status based on loss of nuclear staining, it helps identify patients who may be candidates for immunotherapy.

Idylla CDx MSI Test is an FDA-approved, fully automated real-time PCR assay that analyzes DNA from formalin-fixed, paraffin-embedded tumor tissue to qualitatively determine microsatellite instability (MSI) status. Performed on the Idylla cartridge-based system, it uses a panel of monomorphic markers and integrated analysis software to classify tumors as MSI-high or MSI-stable, supporting prognosis and treatment planning in eligible patients.